GE HealthCare Eyes Sofie Biosciences Acquisition to Expand Imaging Chemicals
GE HealthCare is considering a deal worth up to $1 billion for Sofie Biosciences, which makes radiopharmaceuticals used in cancer PET scans.
/ 3 items
#GEHC↓
GE HealthCare Beats Q2 Estimates on Record Orders, Weighs Sale of Struggling Patient Care Unit
GE HealthCare posts record 11.1% order growth and $5.3B revenue in Q2 2026, beating estimates. Stock jumps as it reviews Patient Care unit sale.
New Partnership Brings Leading Prostate Cancer Detection Tool to Japan
Lantheus licenses PYLARIFY, a leading PSMA PET imaging agent for prostate cancer, exclusively to GE HealthCare for development, manufacturing, and sales in Japan, a key international market.